



Dipeptidyl Peptidase-4 (DPP-4) Inhibitors

Drug Name: Alogliptin, Alogliptin-metformin, Alogliptin-pioglitazone

Effective Date: 05/01/2012

Reviewed Date: 5/2012, 5/2015, 9/2017, 7/2018, 8/2019, 9/2020, 6/2021, 04/2022, 04/2023, 04/2024

Required Medical information:	<ul style="list-style-type: none">• Patient has not achieved adequate glucose control using an adequate/maximized dose and appropriate duration of metformin (2 grams/day); AND• Alogliptin will not be used in conjunction with an GLP-1
Coverage Duration:	<ul style="list-style-type: none">• 12 months

Investigational use: Neighborhood does not provide coverage for drugs when used for investigational purposes. All therapies are considered investigational when used at a dose or for a condition other than those that are recognized as medically accepted indications as defined in any one of the following standard reference compendia: American Hospital Formulary Service Drug information (AHFS-DI), Thomson Micromedex DrugDex, Clinical Pharmacology, Wolters Kluwer Lexi-Drugs, or Peer-reviewed published medical literature indicating that sufficient evidence exists to support use.